欣强电子的主营业务是印制电路板的研发、生产和销售。公司印制电路板产品定位于中高端市场，以八层及以上高端PCB为主， 产品均价超过2,000元/ 平方米，处于行业第一梯队。 据招股书，2022年-2024年，欣强电子实现营收分别为8.69亿元、10亿元、9.99亿元；归母净利润分别为8498.39万元、1.32亿元、1.68亿元。 瑞财经 吴文婷 近日，欣强电子（清远）股份有限公司（以下简称"欣强电子"）创业板IPO申请获受理，保荐机构为民生证券股份有限公司，保荐代表人 为曾文强、帖晓东，会计师事务所为普华永道中天会计师事务所（特殊普通合伙）。 | 项目 | 2024年12月 31 | 2023年12月31 | 2022年12月 31 | | --- | --- | --- | --- | | | 日/2024 年度 | 日/2023 年度 | 日/2022 年度 | | 资产总额(万元) | 111,113.68 | 99,579.93 | 98,929.04 | | 归属于母公司的所有者权益(万元) | 83,713.06 | 66.714.59 | 57.975.25 | | 资产负债率(母公司) | 2 ...

瑞财经 吴文婷7月2日晚，时隔三个月，小米创始人、董事长兼CEO雷军佩戴最新发布小米AI眼镜，开 启返场直播，其介绍了小米YU7的订单、交付情况。 雷军在直播中回应了关于YU7大定数据的质疑："当时发布了大定数据后，我们受到了大量的质疑，有 人说是可退的。所谓的'犹豫期'看上去有点故弄玄虚，其实这是所有车厂都在采用的方式。因此，我们 大定量的统计口径和所有车企都是一样的。" 据了解，6月26日，小米首款SUV车型YU7正式发布上市，起售价25.35万元，该款车型上市即取得亮 眼"战报"。小米汽车官微称，3分钟，小米YU7大定突破20万辆。1小时，大定突破28.9万辆。开售18小 时，小米YU7锁单量突破24万辆。 ml 小米汽车 窗 25-6-27 16:11 发布于 北京 来自 Xiaomi 14 Ultra 已编辑 十关注 开售18小时, #小米YU7# 锁单量已突破240000台, 真诚感谢每一位朋友的支持。 (mg EE 22416 同时，其还透露了YU7的用户画像。小米YU7车主的平均年龄约为33岁，比小米SU7用户大三岁；女性 车主的比例为30%，比小米SU7的首销期大概高出4.5%。在小米YU7 ...

Group 1: New Housing Market - The new housing market in Beijing has shown signs of stability, with a total transaction area of 2.67 million square meters in the first half of the year, reflecting a year-on-year increase of 3% [2] - Six new housing projects achieved sales exceeding 4 billion yuan, indicating a strong performance in high-quality improvement properties [2][3] - The high-end segment of the new housing market has seen significant growth, with transactions for properties priced between 10 million to 20 million yuan increasing by nearly 90% year-on-year, raising its market share from 12% in 2024 to approximately 19% [3] Group 2: Land Supply and Transactions - In the first half of the year, Beijing completed 22 residential land transactions, with a total transaction value of 100.56 billion yuan, a year-on-year increase of 37.3% [4] - The land auction market has shown a trend of "volume shrinking but price rising," with several core and high-value plots being sold, indicating strong demand despite reduced supply [4] Group 3: Second-hand Housing Market - The second-hand housing market in Beijing has seen a significant increase, with a total of 88,575 transactions in the first half of the year, representing an 18% year-on-year growth [6] - The majority of buyers in the second-hand market are first-time homebuyers, with over 60% of transactions being for properties priced below 5 million yuan [6][5] - The second-hand market is characterized by a "price for volume" approach, with average prices showing slight declines due to high inventory levels [7] Group 4: Market Outlook - The current reasonable price levels in the second-hand market are expected to maintain stable transaction volumes, with suggestions for policy adjustments to control new housing supply and enhance support for homebuyers [8]

PRAME Franchise & Market Opportunity - Immatics is developing three clinical product candidates (IMA402, IMA203, IMA203CD8) precisely targeting PRAME, an intracellular protein presented on tumor cell surfaces[10, 12] - PRAME expression is prevalent in over 50 cancers[8], with prevalence ranging from 20% in Hepatocellular Carcinoma and Bladder Carcinoma to 95% in Cutaneous Melanoma, Uterine Carcinoma, and Synovial Sarcoma[9] - The addressable PRAME+/HLA-A*02:01+ patient population in the US & EU5 is estimated to be approximately 230,000 per year[20, 24] IMA203 PRAME Cell Therapy (Wave 1) - In a Phase 1 study, IMA203 demonstrated a confirmed objective response rate (cORR) of 56% (18/32) in heavily pretreated patients with metastatic melanoma[34, 45] - The median duration of response (mDOR) was 121 months, with ongoing responses for up to 25+ years[34] - The median progression-free survival (mPFS) was 61 months, and the median overall survival (mOS) was 159 months in all melanoma patients[34, 51] - The SUPRAME Phase 3 trial is actively enrolling patients with unresectable or metastatic melanoma post-ICI, with a planned launch in Q3 2027[35, 59] - Approximately 9,000 PRAME+/HLA-A*02:01+ patients in the US/EU5 with cutaneous and uveal melanoma are addressable[34] IMA203CD8 PRAME Cell Therapy (GEN2) (Wave 2) - IMA203CD8 is a next-generation PRAME cell therapy leveraging CD8 and CD4 T cells, with enhanced pharmacology[24] - In a Phase 1a dose escalation study, IMA203CD8 achieved a cORR of 41% (14/34) at presumably suboptimal doses, with 84% (32/38) of patients experiencing tumor shrinkage[73, 85] - The median duration of response (mDOR) was 92 months, with 3 confirmed responses ongoing at 1+ year[73, 85] - The addressable PRAME+/HLA-A*02:01+ patient opportunity for IMA203CD8 is approximately 75,000 per year, including indications with both high and medium-level PRAME expression[20, 68] IMA402 PRAME Bispecific (Wave 3) - IMA402 is a next-generation half-life extended bispecific primarily targeting first-line settings in combination with ICI and targeted agents[22] - Early signs of clinical activity have been observed, with a melanoma patient achieving a confirmed partial response ongoing at 3 months at DL7[115] - The addressable PRAME+/HLA-A*02:01+ patient population for IMA402 in 1L solid tumors is approximately 145,000 in the US & EU5[20, 100] Beyond PRAME: IMA401 MAGEA4/8 Bispecific - IMA401 is a bispecific targeting MAGEA4/8, with a Phase 1a study demonstrating a 29% (5/17) ORR and 25% (4/16) cORR in patients with MAGEA4/8high expression at relevant doses[132, 149] - The addressable MAGEA4/8+ and HLA-A*02:01+ patient population in the US & EU5 is approximately 62,000 per year[128, 130]

Business Overview - U.S net product revenue of NEXLETOL® and NEXLIZET® grew by 12% from Q3 2021 to $12.2 million in Q4 2021[10] - Sequential prescription growth of 9% from Q3 2021 with over 70,000 cumulative patients[10] - CLEAR Outcomes trial reached 90% MACE Accumulation in February 2022, with topline results expected in Q1 2023[10, 16] Financial Update - Ended Q4 2021 with $309.3 million in cash, cash equivalents, restricted cash and investment securities[10] - FY 2021 Operating Expenses were $305 million[22] - FY 2022 R&D Guidance is $100 - $110 million[22] - FY 2022 SG&A Guidance is $120 - $130 million[22] - Future Ex-U.S Collaboration Milestones from Daiichi Sankyo & Otsuka are >$1.2 billion[22] - Q4 2021 Common Shares Outstanding were 60.9 million[22]

Business Highlights - Approximately 35 million patients are considered statin intolerant in the U S, Japan, and the EU[8] - Statin intolerance impacts up to 20% of individuals treated with a statin[8, 12] - CLEAR Outcomes trial has enrolled over 14,000 patients and is powered for success[12] - The CLEAR Outcomes trial expects a high baseline LDL-C of approximately 140 mg/dL[12] Operational Performance - Over 8,600 doctors are writing at least one prescription for Esperion's medicines[15] - More than 3,300 patients are taking Esperion's medicines every week[15] - Over 420,000 seven-day starter packs have been requested and received[15] - New-to-brand statin prescriptions are down 9% year-to-date 2021 compared to year-to-date 2020 due to COVID-19 impacts[17] Financial Results & Guidance - U S Net Product Sales increased 14 6% quarter over quarter[23] - Royalty revenues from DSE were $8 2 million in the quarter[23] - Ex-U S Collaboration Milestones were $3 3 million[23] - The company anticipates FY 2021 revenues between $120 - $130 million[26]

FORWARD-LOOKNG STATEMENTS & DISCLOSURES MAY 3, 2022 © 2022 Esperion. All Rights Reserved – For investor audience only WHEN DO YOU PLAN TO GET YOUR NEXT CHOLESTEROL TEST? This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing ...

Core Insights - The Tocotrienol Market is expected to grow from USD 380.60 million in 2025 to USD 528.59 million by 2030, representing a CAGR of 6.79% driven by increasing consumer awareness of health and wellness [2] - The demand for tocotrienols is rising in both dietary supplements and cosmetics due to their health benefits and antioxidant properties [3][5] Market Dynamics - The growth of the tocotrienol market is fueled by heightened awareness of its health benefits, particularly in disease management, and the increasing demand for anti-aging products [5][7] - Key players in the market are investing in R&D to innovate and differentiate their product offerings, with a focus on natural and functional ingredients [3][4] Regional Insights - The Asia-Pacific region, especially China, is a leading market for tocotrienols, supported by a growing focus on functional foods and nutritional supplements [6] - Japan's aging population, where 29% are over 60, is contributing to the demand for tocotrienols due to their health benefits [6] Competitive Landscape - Major players in the tocotrienol market include BASF SE, Fuji Chemical Industries Co. Ltd, and ExcelVite Sdn. Bhd., who are expanding production capabilities while adhering to safety standards [4][8] - The market is characterized by competitive dynamics, with companies adopting various strategies to enhance their market positioning [8]

【环球网科技综合报道】7月3日消息，据外媒9to5mac报道称， 2025 年已过半，苹果在产品创新上持续发力，计划于今年秋季推出超 15 款新产品。 外媒称，此次苹果可穿戴设备将迎强劲更新，Apple Watch Ultra 3 将配备 5G RedCap、高血压传感器和卫星功能，Apple Watch Series 11 和 SE 3 也将升级； AirPods Pro 3 将搭载 H3 处理器并升级降噪功能。 据介绍，苹果将推出至少两款智能家居新品，包括新款 Apple TV 4K（配备 A 级芯片和 Apple Intelligence 功能）、HomePod mini 2（搭载全新 Wi-Fi 调制解 调器）以及可能的 "HomePad" 智能家居指挥中心。 苹果还将发布 AirTag 2（配备新型超宽带芯片）、M5 Vision Pro（规格提升）和 Studio Display 2（采用 MiniLED 技术并改进摄像头）。此外，有传言称苹 果可能推出 Pro Display XDR 2，以搭配新款 Mac Pro。（青云） 其中，苹果将推出 iPhone 17 系列，包括 iPhone 17、 ...

作为大模型领域的年度风向标，论坛每年吸引超3000多人报名、100家主流媒体报道，覆盖面超200000 人次。历届成果被央视、新华社、智通财经等媒体广泛报道，相关话题全网阅读量突破3百万次，更推 动超30家企业加速布局大模型应用，促成多项技术合作项目落地。 中国信通院作为权威智库机构，在大模型技术探索与应用方面始终处于领先地位，并取得了丰硕成果。 华东分院已连续七年支撑WAIC核心论坛，见证并推动了人工智能从基础研究到实际应用的每一步发 展，此次论坛是我院落实国家人工智能发展战略、抢占全球技术制高点的关键举措，将统筹全院科研力 量，整合多部门资源，打造大模型技术攻关与产业赋能的"国家队"。 本次论坛将汇聚全球顶尖外籍嘉宾、学者、行业领袖、AI领域权威专家将带来前沿洞察，头部企业代 表将深度解析大模型技术的突破性进展与产业落地实践，形成"政产学研用"多方智慧交融的顶级对话平 台，为全球大模型发展提供中国方案。 论坛期间将集中发布多项前沿研究成果，涵盖"人工智能+"融合应用、终端智能体安全、垂直领域大模 型创新实践等多个关键方向。这些重磅成果将为大模型在垂直行业的规模化落地提供可复制、可推广的 解决方案。 202 ...